Viridian Therapeutics misses Q4 estimates
Source: SeekingAlpha
2026-02-26 07:45:53 ET
More on Viridian Therapeutics
- Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)
- Seeking Alpha’s Quant Rating on Viridian Therapeutics
- Historical earnings data for Viridian Therapeutics
- Financial information for Viridian Therapeutics
Read the full article on Seeking Alpha
For further details see:
Viridian Therapeutics misses Q4 estimates
Viridian Therapeutics Inc Com
NASDAQ: VRDN
VRDN Trading
-2.0% G/L:
$27.25 Last:
98,815 Volume:
$27.69 Open:
VRDN Latest News
February 26, 2026 07:01:00 am
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
VRDN Stock Data
$2,867,173,362
93,934,024
4.1%
67
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
